Multiple Sclerosis (MS) News: Breaking Multiple Sclerosis (MS) News, Comments and Articles. - Page: 4

Xenetic Biosciences enjoys diverse portfolio, reckons broker

With its diverse product portfolio, Xenetic Biosciences (LON:XEN) has multiple opportunities to create value, says broker N+1 Singer, after the firm posted its 2012 numbers. Key drivers in the short term will be the start of phase II trials for Erepo...

United Spinal Statement Hails Court Of Appeals Ruling To Add Accessible Taxis

NEW YORK, June 7, 2013 /PRNewswire-USNewswire/ -- United Spinal Association celebrates the Court of Appeals decision to reinstate a law passed over a year ago that would give wheelchair users access to yellow taxis in New York City and liveries beyond Manhattan. (Logo:  http://photos.prnewswire.com/prnh/20110413/MM82757LOGO) Currently, only 232 taxis out of approximately 13,000 y...

Phase 1 Multiple Sclerosis Trial Safely Resets Patients' Immune Systems And Reduces Attack On Myelin Protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent, according to new...

[Glaxo] gets global rights to [MorphoSys]’ rheumatoid arthritis antibody MOR103

[MorphoSys AG] (fully human antibody technologies) has granted [GlaxoSmithKline PLC] worldwide rights to its lead candidate MOR103, in Phase I/II for mild-to-moderate rheumatoid arthritis, and in Phase I for multiple sclerosis.

Xenetic Biosciences sees benefits of becoming US-centric organisation

After positive developments in the year gone, Xenetic Biosciences (LON:XEN) is moving towards its rebirth as a specialty drug developer  working with partners in Russia, India and the United States. Releasing its 2012 results, the firm also upda...

Santhera gets exclusive rights from NIH for novel approach to pp multiple sclerosis treatment

Swiss Santhera Pharmaceuticals (SIX: SANN) says that it has obtained an exclusive license from the USA's National Institutes of Health (NIH) to its rights on a patent granted in the USA for the use of idebenone for the treatment of primary progressiv...

Multiple Sclerosis Breakthrough Finishes Phase 1 With Flying Colors

Lee Rannals for redOrbit.com – Your Universe Online Northwestern Medicine researchers say they have discovered a big breakthrough that could help people suffering from multiple sclerosis (MS). The researchers completed the first phase of a clinical trial for the first treatment to reset the immune system of MS patients. They found that the patients showed the therapy was safe and dramatically...

Cowen Questions Sales Growth Of Biogen Idec's MS Drug Tecfidera

By Brian L. Wilson:Earlier this week, Biogen Idec (NASDAQ: BIIB) was the worst performer aming the larger pharmaceutical companies after Cowen analyst Eric Schmidt pointed that the IMS prescription sales data for new prescriptions (NRx) of the company's recently launched multiple sclerosis / MS drug Tecfidera (dimethyl fumarate) may be flawed due to double counting of patients who were prescribed...

Chicago Crime Commission calls on Gov. Quinn to veto medical marijuana bill

CHICAGO, June 6, 2013 /PRNewswire-USNewswire/ -- The Chicago Crime Commission joined the Illinois Sheriffs' Association and the Illinois Association of Chiefs of Police by calling on Governor Pat Quinn to veto legislation that would legalize medical marijuana in Illinois.  If signed into law, there is fear that House Bill 1 will present serious public safety risks to the citizens of the state...

Santhera Secures Exclusive Rights from NIH for a Novel Approach for the Treatment of Primary Progressive MS

Santhera Pharmaceuticals Holding AG / Santhera Secures Exclusive Rights from NIH for a Novel Approach for the Treatment of Primary Progressive MS . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Liestal, Switzerland, June 6, 2013 -Santhera Pharmaceuticals (SIX: SANN) announced today that it has obtained an exclusive lice...

Research Fraud at GSK Shanghai?

This is quite bad. Reports have been circulating that GlaxoSmithKline is investigating the scientists (and the results) behind this 2010 paper in Nature Medicine. That first link from Pharmalot mentions this thread at the Chinese mitbbs.com site, an...

MS Treatment That Resets Immune System Shows Promise In Safety Trial

A new treatment for multiple sclerosis (MS) that resets the patient's immune system was found to be safe and well tolerated in a small trial published in Science Translational Medicine this week. And, although not designed to test the effectivenes...

LAM Therapeutics Launches Operations to Develop Drugs for Rare Lung Disease, Lymphangioleiomyomatosis (LAM)

GUILFORD, CT -- (Marketwired) -- 06/06/13 -- LAM Therapeutics, the first biopharmaceutical company dedicated to identifying and developing drugs for the treatment of Lymphangioleiomyomatosis (LAM), announced today that it has closed a Series A financing with private investors to launch operations. Proceeds from the financing will be used for identification of clinical stage drugs with potential a...

RedHill Biopharma begins patient screening for Phase IIa multiple sclerosis trial

Israeli biopharmaceutical company RedHill Biopharma has started screening patients for a Phase IIa trial designed to evaluate the efficacy and safety of RHB-104 in multiple sclerosis.

Big multiple sclerosis breakthrough

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent, according to new...

Tysabri Screening Test May Be Unreliable (CME/CE)

(MedPage Today) -- About one-third of multiple sclerosis patients testing negative for antibodies against the JC virus -- suggesting that natalizumab (Tysabri) would be relatively safe -- were found to have active viremia.

Multiple sclerosis breakthrough: Trial safely resets patients' immune systems and reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent, according to new...

Multiple sclerosis: Phase 1 trial safely resets patients' immune systems, reduces attack on myelin protein

A phase 1 clinical trial for the first treatment to reset the immune system of multiple sclerosis (MS) patients showed the therapy was safe and dramatically reduced patients' immune systems' reactivity to myelin by 50 to 75 percent. The therapy used...

Prime Therapeutics' specialty pharmacy receives URAC accreditation

ST. PAUL, Minn., June 5, 2013 /PRNewswire/ -- Prime Therapeutics (Prime), a leading pharmacy benefit manager (PBM), announced today that its specialty pharmacy, Prime Therapeutics Specialty Pharmacy, has received full accreditation from URAC. URAC is a Washington, DC-based health care accrediting organization that establishes quality standards for the health care industry.  "URAC...

New data show Novartis' Gilenya benefited patients by improving all four key measures of RMS

Swiss drug major Novartis' (NOVN: VX) says that its blockbuster drug Gilenya (fingolimod), the first once-daily oral therapy approved to treat people with relapsing multiple sclerosis (RMS), positively impacted the key measures for multiple sclerosis...

New data for Novartis’ Gilenya shows further benefits to MS patients

Novartis has released new data showing that its drug Gilenya benefited patients by improving all four key measures of multiple sclerosis (MS).Gilenya (fingolimod) is the first once-daily oral therapy approved to treat people with relapsing multiple s...

New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis

Novartis International AG / New data at ENS show Novartis drug Gilenya benefited patients by improving all four key measures of multiple sclerosis . Processed and transmitted by Thomson Reuters ONE. The issuer is solely responsible for the content of this announcement. Gilenya improved the key measures: brain volume loss, MRI lesion activity, relapse rates and disability progression Switching...

New Horizon Security Donates Security Services to Bike MS Ride Virginia

New Horizon Security Services, Inc. donated security services to the 2013 Bike MS: Ride Virginia charity event. The annual two-day event raises money and awareness for Multiple Sclerosis research in hopes of one day finding a cure. Richmond, VA (PRWEB) June 05, 2013 New Horizon Security Services, Inc., a family-owned and operated professional security services firm, donated security services to...

New approach in treating multiple sclerosis

In his article, "Pathoetiology of multiple sclerosis: are we barking up the wrong tree?", Peter K. Stys of the Hotchkiss Brain Institute, University of Calgary, argues that while the majority of the medical research community currently approaches MS...

Novartis says study shows Gilenya benefits patients with MS

ZURICH (Reuters) - Novartis said studies show its Gilenya drug helped keep patients with multiple sclerosis free of the disease.